About Livera
Advancing AI-driven Dual-Function RNA Therapeutics for High-Impact Diseases.
Livera Thera is a biotech company developing dual-function RNA therapeutics designed to reduce disease-driving antigen or pathological protein burden while activating immune-mediated clearance.
Our initial focus is chronic hepatitis B, where our platform is designed to lower viral antigen expression and support antiviral immune reactivation. Over time, we aim to extend this dual-function strategy into Alzheimer’s disease and oncology, where reducing pathological burden and restoring immune activity may open new therapeutic possibilities.
Our Mission
Our mission is to develop next-generation RNA medicines that address two fundamental drivers of difficult diseases: persistent molecular burden and impaired immune clearance.
By combining AI-assisted target discovery, rational RNA design, and immune-modulating therapeutic strategies, Livera Thera aims to build a dual-function platform for chronic hepatitis B, Alzheimer’s disease, and cancer.
Why Dual-Function RNA Therapeutics
Molecular Burden
Many chronic and complex diseases are driven by persistent viral antigens, pathological proteins, or disease-associated molecular signals that disrupt normal cellular and immune function.
Immune Dysfunction
In viral infection, neurodegeneration, and cancer, immune responses may become exhausted, suppressed, or ineffective, limiting the body’s ability to clear disease-associated targets.
Dual-Function Strategy
Livera Thera is developing RNA-based therapeutic approaches designed to reduce disease-driving molecular burden while supporting controlled, disease-relevant immune activation.
Our Platform
Livera Thera is building an AI-assisted RNA therapeutics platform that integrates target discovery, sequence conservation analysis, oligonucleotide design, off-target assessment, immune-response profiling, and translational validation.
01
AI Target Screening
Identify conserved, disease-relevant, and therapeutically actionable targets across viral infection, neurodegeneration, and oncology.
02
siRNA Candidate Design
Design and optimize RNA-based molecules with improved potency, specificity, developability, and potential for disease-specific immune modulation.
03
Dual-Function Strategy
Develop therapeutic candidates that combine molecular burden reduction with immune-mediated clearance or immune reactivation.
Our Vision
We envision a new generation of RNA therapeutics that can both reduce disease-driving molecular burden and help the immune system regain its ability to clear, control, and fight disease.
Starting with chronic hepatitis B and expanding toward Alzheimer’s disease and cancer, Livera Thera aims to build a differentiated dual-function RNA therapeutics platform for patients with significant unmet medical needs.